Nemolizumab, which targets the interleukin-31 pathway, rapidly improves itch and sleep in people with atopic dermatitis and ...

Here are our top highlights from AAD 2025 that include safety of topical JAK inhibitors, climate impacts on skin health, ...

Baricitinib was generally well-tolerated. Acne was the most common adverse event (17.6%), followed by dyslipidemia (7.8%). Asthenia, elevated liver enzymes, and weight gain each occurred in fewer than ...

Côte St. Luc City speaks out on Chanukah massacre in Australia ...

Libtayo's approval for high-risk cutaneous squamous cell carcinoma offers a new immunotherapy option, targeting PD-1 ...

Atopic dermatitis’ (AD) deeper complexities were exposed in 2025. Once seen mainly as a visible skin condition, AD is now widely recognized as a long-lasting inflammatory disease that affects sleep, ...

Once limited to nonspecific anti-inflammatory therapies, expanding treatment options for atopic dermatitis are allowing therapy to be individualized.

Medical and health news service that features the most comprehensive coverage in the fields of neuroscience, cardiology, cancer, HIV/AIDS, psychology, psychiatry, dentistry, genetics, diseases and ...

IL-31 is a neuroimmune cytokine that drives itch and other symptoms in both atopic dermatitis and prurigo nodularis. 3,4 These new findings reinforce the critical role of IL-31 pathway inhibition in ...

A German multicentre study reveals strong patient demand for systemic therapy in atopic dermatitis and psoriasis. Learn more about treatment preferences and drivers.

There is little awareness, particularly among clinicians, of the medical and psychological complexities of "topical steroid ...

Sleep loss from itching is one of the hardest parts of caring for a child with eczema. Here’s a guide to relieving night flares — and helping the whole family rest easier.